Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis

[PR Newswire] – THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ — Amgen (AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis Similar Articles: Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 Stock Update: Eli Lilly and Company (NYSE:LLY) – U.S. FDA to phase out some antibiotic use in animal production Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Sobi’s partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting